Fig. 6 | Scientific Reports

Fig. 6

From: Human type I interferons protect Vero E6 and ARPE-19 cells against West Nile virus and are neutralized by pathogenic autoantibodies

Fig. 6

Blocking of IFN-β activity utilizing sera from patients with WNV neuroinvasive disease. The rate of WNV infection, evaluated through virus-induced cytopathic effects 24 h post-infection in ARPE-19 cells treated with different concentrations of IFN-β (10,000, 500, 100, and 50 pg/mL), was examined. Increased WNV replication was observed when ARPE-19 cells were treated with IFN-β in conjunction with serum from a neuroinvasive WNV disease patient carrying neutralizing auto-antibodies (IFN-I-NTAbs) against IFN-β (n = 1). The neutralizing activity of this serum was evident at IFN-β concentrations up to 100 pg/mL, as shown by the ARPE-NT assay. This effect was compared to cells treated with sera from WNV disease patients without IFN-I-NTAbs (n = 2), which served as controls. All sera were tested at a single dilution of 1:10. All experiments were performed in triplicate.

Back to article page